Cargando…
Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates
The development of a new generation of coagulation factors with improved pharmacokinetic profile will change the paradigm of treatment of persons with hemophilia (PWH). The standard treatment in PWH is represented by regular long-term prophylaxis that, given intravenously twice or thrice weekly, is...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406771/ https://www.ncbi.nlm.nih.gov/pubmed/28350322 http://dx.doi.org/10.3390/jcm6040039 |